#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

C-reactive protein to albumin ratio predicts the outcome in renal cell carcinoma: A meta-analysis


Autoři: Wei Zhou aff001;  Guang-lin Zhang aff002
Působiště autorů: Department of Urology, Huangshi Central Hospital (Pu Ai Hospital), Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei,China aff001;  Department of Abdominal and Pelvic Medical Oncology II ward, Huangshi Central Hospital (Pu Ai Hospital), Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei, China aff002
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0224266

Souhrn

Background

Growing evidence has revealed that pretreatment C-reactive protein to albumin ratio (CAR) are associated with prognosis for patients with renal cell carcinoma (RCC). However, inconsistent findings have been reported, which promote us to summarize the global predicting role of CAR for survival in RCC patients.

Methods

Two reviewers independently retrieved the literature on EMBASE, MEDLINE, and Cochrane Library databases for eligible studies evaluating the associations of CAR with survival. Data related to the overall survival (OS), disease-free survival (DFS), progress-free survival (PFS), and clinicopathological features were extracted and pooled using meta-analysis with fixed or random- effect models when applicable.

Results

Eight studies including 2,829 patients were analyzed in the present study. High pretreatment CAR was associated with worse OS (pooled HR: 2.14, 95% CI = 1.64–2.79, p < 0.001) and DFS/PFS (pooled HR: 1.75, 95% CI: 1.31–2.35, P < 0.001). Moreover, high CAR was correlated with performance status (≥ 1), tumor location (left), Fuhrman grade (3–4), TNM stage (III-IV), T stage (T3-4), N stage (N1), M stage (M1), tumor necrosis (yes), venous thrombus (positive), metastasis at diagnosis (yes), NLR (> median), and PLR (> median).

Conclusion

High pretreatment CAR is effectively predictive of worse survival in patients with RCC and could be a prognostic biomarker for those patients.

Klíčová slova:

Albumins – Histology – Inflammation – Metastasis – Renal cell carcinoma – Surgical and invasive medical procedures – Surgical oncology


Zdroje

1. Kuusk T, Grivas N, de Bruijn R, Bex A. The current management of renal cell carcinoma. Minerva Med. 2017;108(4):357–69. doi: 10.23736/S0026-4806.17.05058-3 28176516

2. Cella D, Grunwald V, Nathan P, Doan J, Dastani H, Taylor F, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):994–1003. Epub 2016/06/11. doi: 10.1016/S1470-2045(16)30125-5 27283863; PubMed Central PMCID: PMC5521044.

3. Wu Y, Wang YQ, Weng WW, Zhang QY, Yang XQ, Gan HL, et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls. Oncogenesis. 2016;5:e192. Epub 2016/02/16. doi: 10.1038/oncsis.2015.48 26878386; PubMed Central PMCID: PMC5154346.

4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. Epub 2010/03/23. doi: 10.1016/j.cell.2010.01.025 20303878; PubMed Central PMCID: PMC2866629.

5. Ohmura H, Uchino K, Kajitani T, Sakamoto N, Baba E. Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma. Mol Clin Oncol. 2017;6(5):669–75. Epub 2017/05/19. doi: 10.3892/mco.2017.1205 28515920; PubMed Central PMCID: PMC5431320.

6. Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S, et al. Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2018;16(6):e1151–e8. Epub 2018/09/15. doi: 10.1016/j.clgc.2018.07.027 30213543.

7. Fukuda H, Takagi T, Kondo T, Shimizu S, Tanabe K. Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Oncotarget. 2018;9(18):14296–305. Epub 2018/03/28. doi: 10.18632/oncotarget.24507 29581844; PubMed Central PMCID: PMC5865670.

8. Komura K, Hashimoto T, Tsujino T, Muraoka R, Tsutsumi T, Satake N, et al. The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan. Annals of surgical oncology. 2019. Epub 2019/06/27. doi: 10.1245/s10434-019-07530-5 31240592.

9. Konishi S, Hatakeyama S, Tanaka T, Ikehata Y, Tanaka T, Hamano I, et al. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma. International journal of urology: official journal of the Japanese Urological Association. 2019. Epub 2019/07/26. doi: 10.1111/iju.14078 31342557.

10. Tsujino T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, et al. C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma—A data from multi-institutional study in Japan. Urol Oncol. 2019. Epub 2019/05/06. doi: 10.1016/j.urolonc.2019.04.002 31053528.

11. Barua SK, Singh Y, Baruah SJ, T PR, Bagchi PK, Sarma D, et al. Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience. World J Oncol. 2019;10(2):101–11. Epub 2019/05/10. doi: 10.14740/wjon1188 31068990; PubMed Central PMCID: PMC6497011.

12. Agizamhan S, Qu F, Liu N, Sun J, Xu W, Zhang L, et al. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients. BMC Urol. 2018;18(1):60. Epub 2018/06/13. doi: 10.1186/s12894-018-0374-z 29890986; PubMed Central PMCID: PMC5996532.

13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi: 10.1007/s10654-010-9491-z 20652370.

14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34. doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 9921604.

15. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16 17555582; PubMed Central PMCID: PMC1920534.

16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. Epub 1986/09/01. 3802833.

17. Guo S, He X, Chen Q, Yang G, Yao K, Dong P, et al. The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer. 2017;17(1):171. Epub 2017/03/08. doi: 10.1186/s12885-017-3119-6 28264659; PubMed Central PMCID: PMC5339967.

18. Gao J, Agizamhan S, Zhao X, Jiang B, Qin H, Chen M, et al. Preoperative C-reactive protein/albumin ratio predicts outcome of surgical papillary renal cell carcinoma. Future Oncol. 2019;15(13):1459–68. Epub 2019/04/13. doi: 10.2217/fon-2018-0611 30977386.

19. Chen Z, Shao Y, Fan M, Zhuang Q, Wang K, Cao W, et al. Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(11):14893–900. Epub 2016/01/30. 26823819; PubMed Central PMCID: PMC4713605.

20. Xu HJ, Ma Y, Deng F, Ju WB, Sun XY, Wang H. The prognostic value of C-reactive protein/albumin ratio in human malignancies: an updated meta-analysis. Onco Targets Ther. 2017;10:3059–70. doi: 10.2147/OTT.S137002 28790840.

21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. Epub 2011/03/08. doi: 10.1016/j.cell.2011.02.013 21376230.

22. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. Epub 2014/10/05. doi: 10.1016/S1470-2045(14)70263-3 25281468.

23. Chen Z, Wang K, Lu H, Xue D, Fan M, Zhuang Q, et al. Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis. Cancer Manag Res. 2019;11:909–19. Epub 2019/01/31. doi: 10.2147/CMAR.S186976 30697081; PubMed Central PMCID: PMC6342149.

24. Kim TW, Lee JH, Shim KH, Choo SH, Choi JB, Ahn HS, et al. Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma. Investigative and clinical urology. 2019;60(1):14–20. Epub 2019/01/15. doi: 10.4111/icu.2019.60.1.14 30637356; PubMed Central PMCID: PMC6318207.

25. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–6. Epub 2009/03/26. doi: 10.1097/MCO.0b013e32832a7902 19318937.

26. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. Epub 2002/12/20. doi: 10.1038/nature01322 12490959; PubMed Central PMCID: PMC2803035.

27. Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PloS one. 2013;8(3):e59321. Epub 2013/04/05. doi: 10.1371/journal.pone.0059321 23555017; PubMed Central PMCID: PMC3595283.

28. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Annals of surgical oncology. 2015;22(3):803–10. Epub 2014/09/06. doi: 10.1245/s10434-014-4048-0 25190127.

29. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer. 1992;70(3):709–13. Epub 1992/08/01. doi: 10.1002/1097-0142(19920801)70:3<709::aid-cncr2820700328>3.0.co;2-o 1320454.

30. Ruscetti FW. Hematologic effects of interleukin-1 and interleukin-6. Curr Opin Hematol. 1994;1(3):210–5. Epub 1994/05/01. 9371284.

31. Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-Reactive Protein and Breast Cancer: New Insights from Old Molecule. Int J Breast Cancer. 2015;2015:145647. Epub 2015/12/23. doi: 10.1155/2015/145647 26693355; PubMed Central PMCID: PMC4674617.

32. Wang Z, Peng S, Wang A, Xie H, Guo L, Jiang N, et al. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis. Clin Chim Acta. 2017;475:178–87. Epub 2017/10/31. doi: 10.1016/j.cca.2017.10.021 29080691.

33. Takamatsu K, Mizuno R, Omura M, Morita S, Matsumoto K, Shinoda K, et al. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy. Clin Genitourin Cancer. 2018;16(4):e927–e33. Epub 2018/04/22. doi: 10.1016/j.clgc.2018.03.012 29678472.

34. Caraceni P, Tufoni M, Bonavita ME. Clinical use of albumin. Blood Transfus. 2013;11 Suppl 4:s18–25. Epub 2013/12/18. doi: 10.2450/2013.005s 24333308; PubMed Central PMCID: PMC3853979.


Článek vyšel v časopise

PLOS One


2019 Číslo 10
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

KOST
Koncepce osteologické péče pro gynekology a praktické lékaře
nový kurz
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Svět praktické medicíny 5/2023 (znalostní test z časopisu)

Imunopatologie? … a co my s tím???
Autoři: doc. MUDr. Helena Lahoda Brodská, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#